Author | Spinasse, Lizania Borges | |
Author | Santos, Adalberto Rezende | |
Author | Suffys, Philip Noel | |
Author | Muxfeldt, Elizabeth Silaid | |
Author | Salles, Gil Fernando | |
Access date | 2015-05-04T17:07:32Z | |
Available date | 2015-05-04T17:07:32Z | |
Document date | 2014 | pt_BR |
Citation | SPINASSE, Lizania Borges et al. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. Pharmacogenomics, v.15, n.2, p.169-178, 2014. | pt_BR |
ISSN | 1462-2416 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/10214 | |
Language | eng | pt_BR |
Publisher | Future Medicine Ltd | pt_BR |
Rights | open access | pt_BR |
Subject in Portuguese | Hidralazina | pt_BR |
Subject in Portuguese | Hipertensão | pt_BR |
Subject in Portuguese | Brasil | pt_BR |
Subject in Portuguese | População | pt_BR |
Title | Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension | pt_BR |
Type | Article | pt_BR |
DOI | 10.2217/pgs.13.202 | pt_BR |
Abstract | Aim: Hydralazine, a vasodilator used in resistant hypertension (RH) treatment is metabolized by an
acetylation reaction mediated by N-acetyltransferase 2, the activity of which depends on NAT2
polymorphisms. Our aim was to evaluate whether different acetylation phenotypes influenced the
antihypertensive effect of hydralazine in patients with RH. Patients & methods: DNA samples from 169
RH patients using hydralazine were genotyped by sequencing the NAT2 coding region, and acetylation
phenotypes were defined. Results: Sixty-five patients (38.5%) were intermediate, 60 (35.5%) slow and 21
(12.4%) fast acetylators. Twenty-three (13.6%) patients were indeterminate. Upon association analysis,
only slow acetylators had significant blood pressure reductions after hydralazine use, with mean 24-h
systolic and diastolic blood pressure reductions of 9.2 and 5.5 mmHg. Four patients presented hydralazine
adverse effects resulting in drug withdrawal, three of them were slow acetylators. Conclusion: The slow
acetylation phenotype, determined by polymorphisms within NAT2, influenced both the antihypertensive
and adverse effects of hydralazine in RH. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular Aplicada em Micobactérias . Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular Aplicada em Micobactérias . Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular Aplicada em Micobactérias . Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Escola de Medicina. Hospital Universitário Clementino Fraga Filho. Departamento de Medicina Interna. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Escola de Medicina. Hospital Universitário Clementino Fraga Filho. Departamento de Medicina Interna. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | Brazilian population | pt_BR |
Subject | Hydralazine | pt_BR |
Subject | NAT2 polymorphism | pt_BR |
Subject | Resistant hypertension | pt_BR |
Subject | SNP | pt_BR |
Subject in Spanish | Hidralazina | pt_BR |
Subject in Spanish | Hipertensión | pt_BR |
Subject in Spanish | Brasil | pt_BR |
Subject in Spanish | Población | pt_BR |
DeCS | Ciências Biológicas | pt_BR |
DeCS | Hidralazina | pt_BR |